Artificial Intelligence for Precision Health: Current Trends, Lingering Challenges, and Future Possibilities
Artificial Intelligence (AI) has been fast growing in many fields all over the world. How has health data been utilized to develop AI for precision health and what are the challenges in different countries? Join leading data science experts from the US and China to hear their perspectives on the present and the future of AI in their respective countries. This event is part of the JI's Trusted Conversations roundtable series.
Dr. Luxia Zhang is the professor of Nephrology at Peking University First Hospital, and the Vice Dean of National Institute of Health Data Science at Peking University. She obtained her MD degree at Peking University; and her MPH degree at Harvard School of Public Health. For the last fifteen years, her research has focused on prevalence, risk factors, intervention and management of kidney disease in China, and the application of cutting-edge technology including big data and artificial intelligence in healthcare. Her studies have been published in top medical journals including NEJM, Lancet and BMJ. She received 2016 Young Investigator Award by Chinese Society of Nephrology. She is the Vice President and Secretary-General of Health Data Application and Management Committee at Chinese Hospital Association, the Vice President of Committee on Health Data Science and Digital Medicine at China International Exchange and Promotion Association for Medicine and Healthcare, and the Vice President of Beijing Young Nephrologists Society.
Dr. Brahmajee Nallamothu is an interventional cardiologist and cardiovascular outcomes researcher at the University of Michigan. He has a long-standing interest in improving the use of specialized cardiovascular services in high-risk patients — particularly those with heart attacks or suffering cardiac arrest. His most recent work has focused on combining “Big Data” tools with qualitative approaches. He is the Editor-in-Chief of Circulation: Cardiovascular Quality & Outcomes, a journal of the American Heart Association. His work has been funded by the NIH, AHRQ, VA HSRD, and AHA.
Dr. Brian Athey is the Michael A. Savageau Collegiate Professor and Founding Chair of the Department of Computational Medicine and Bioinformatics at the University of Michigan (UM) Medical School. In addition, he served as co-founder and co-director of the UM-wide Michigan Institute for Data Science (MIDAS) from 2015–2018. Dr. Athey has more than 25 years of experience in trans-disciplinary team science-based leadership as overall Principal Investigator of national biomedical informatics and computational sciences centers and consortia. He has contributed to the founding of two new fields of pharmacogenomics (pharmacoepigenomics and pharmacophenomics) that are fundamentally extending its scope and potential impact. Athey has authored more than 120 peer-reviewed papers and conference proceedings. He currently has five issued patents (US, Europe and Asia), with six more in the pipeline under review.